Sushila Dalal - Concepedia

Author

Sushila Dalal

Also Known As

Dalal, S., Jun Huang, Robin Dalal, S Dalal, S R Dalal, S. Dalal, S.R. Dalal, Sebastian Pott, Sushila Dalal, Sushila R Dalal

181

Publications

3.2K

Citations

H-Index

Concepts

All Affiliations

University of Chicago Marine Biological Laboratory Argonne National Laboratory Mayo Clinic Rabin Medical Center

About

Sushila Dalal is an author at University of Chicago specializing in medicine, gastroenterology, and pathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	13	16	1K
2	Health Sciences	3	3	178
3	Cell Biology	2	2	313
4	Public Health	1	1	16
5	Epidemiology	1	1	14

Sushila Dalal

Publications

2.8K

Citations

H-Index

Page 1

	Year	Citations
A possible linkage between AMP‐activated protein kinase (AMPK) and mammalian target of rapamycin (mTOR) signalling pathway Naoki Kimura, Chiharu Tokunaga, Sushila Dalal, Genes to Cells	2003	371
The Microbe-Derived Short Chain Fatty Acid Butyrate Targets miRNA-Dependent p21 Gene Expression in Human Colon Cancer Shien Hu, Tien S. Dong, Sushila Dalal, PLoS ONE DysbiosisPathologyCancer BiologyScfa ButyrateGut-organ Axis	2011	226
Using Corticosteroids to Reshape the Gut Microbiome Edmond Y. Huang, Takuya Inoue, Vanessa Leone, Inflammatory Bowel Diseases	2015	193
The Role of MicroRNA in Inflammatory Bowel Disease. Sushila Dalal, John H. Kwon PubMed	2010	122
Upadacitinib Is Effective and Safe in Both Ulcerative Colitis and Crohn’s Disease: Prospective Real-World Experience Scott Friedberg, David Choi, Thomas Hunold, Clinical Gastroenterology and Hepatology InflammationAnti-inflammatoryProspective Real-world ExperiencePharmacologyGastroenterology	2023	112
An activating mutation in the γ1 subunit of the AMP‐activated protein kinase Stephen R. Hamilton, David Stapleton, John B. O'Donnell, FEBS Letters	2001	111
Comparison of brush and biopsy sampling methods of the ileal pouch for assessment of mucosa-associated microbiota of human subjects Susan M. Huse, Vincent B. Young, Hilary G. Morrison, Microbiome	2014	110
Real-World Experience with Tofacitinib in IBD at a Tertiary Center Roni Weisshof, Maya Aharoni Golan, Philip H. Sossenheimer, Digestive Diseases and Sciences Translational MedicineTertiary CenterMedicineTranslational ResearchPharmacology	2019	102
Effectiveness of Ustekinumab Dose Escalation in Patients With Crohn’s Disease Jacob E. Ollech, Inessa Normatov, Noam Peleg, Clinical Gastroenterology and Hepatology Ustekinumab Dose EscalationGastroenterologyClinical GastroenterologyPharmacotherapyUlcerative Colitis	2020	102
Risk of Postoperative Complications Among Inflammatory Bowel Disease Patients Treated Preoperatively With Vedolizumab Akihiro Yamada, Yuga Komaki, Nayan Patel, The American Journal of Gastroenterology	2017	93

Page 1